To assess the use of donor pigs with cellular chimerism for prevention of acute rejection with modest immune suppression. The clinical use of pig organ xenografts is currently precluded by severe acute rejection, which resists standard immune suppression.
Objective
To assess the use of donor pigs with cellular chimerism for prevention of acute rejection with modest immune suppression. The clinical use of pig organ xenografts is currently precluded by severe acute rejection, which resists standard immune suppression.
Summary Background Data
For long-term survival of pig organ xenografts, immune suppression significantly greater than used with allografts would currently be necessary, leaving the recipient immune deficient and at increased risk for infections. Induction of immune tolerance and tissue accommodation could enhance xenograft survival but would lead to complications and frequent graft failure. Induction of cellular chimerism within the donor pigs, however, could accomplish these goals before transplantation, significantly reducing the risk.
Methods
Marrow cells from sheep were infused into fetal pigs. Heart xenografts from chimeric or nonchimeric pigs were transplanted heterotopically into recipient sheep, simultaneous with infusion of splenocytes. Posttransplant suppression consisted of cyclosporine and tapered corticosteroids, comparable with allotransplants.
Results
All of the control grafts (n ϭ 12) were rejected by acute vascular rejection in 4 to 8 days. In contrast, only one episode of vascular rejection was observed in the experimental group (n ϭ 13). Four experimental recipients had an episode of moderate diffuse cellular rejection (grade 3) and one had moderate focal cellular rejection (grade 2). Each episode responded to pulse steroids. Seven grafts showed no significant rejection. There was little evidence of immune deficiency, infection, or toxicity.
Conclusions
Acute vascular rejection was prevented in a large animal model without the need for severe immune suppression.
The transplantation of organ xenografts from pigs could readily address the severe and growing shortage of human organ donors. Xenotransplantation of vascular organs is not feasible with current technology, however, due to severe acute rejection. In particular, acute vascular rejection (AVR), caused by induced antibodies to porcine endothelial cells, has consistently resisted efforts to prevent rejection. 1 Although the use of transgenic pigs expressing human complement inhibitors has proved effective in preventing hyperacute rejection, these grafts are usually rejected by AVR. 2 Drugs that are effective in preventing allograft rejection are not effective in preventing AVR. 3 Immune tolerance to pig cells could reduce the need for immune suppression. However, the induction of tolerance through bone marrow transplantation subjects the recipient to a period of severe immune deficiency. Furthermore, tolerance to donor hematopoietic cells following bone marrow transplantation of the recipient does not prevent AVR of vascular grafts. 4 If graft rejection by antibodies can be prevented, the graft eventually may become accommodated or resistant to injury. Accommodation has been studied extensively and proposed as a pathway to prolonged xenograft acceptance and prevention of AVR. [5] [6] [7] [8] Engraftment of recipient lymphocytes within donor pigs could reduce the severity of xenograft rejection and the need for severe immune suppression. The lymphocytes would become tolerant to the donor tissue antigens as well as the hematopoietic cells. The specific suppressor cells could then be transferred back to the recipient. The porcine tissues could also become accommodated within the chimeric donor, before the transplantation. They would then resist injury by formed and developing antibodies following transplantation.
Billingham et al. demonstrated that the environment during early immune ontogeny is conducive to immune tolerance. 9 The fetus or newborn develops specific tolerance to exposed antigens, including injected cells. In our previous studies with fetal pigs, tolerance of the injected lymphocytes to the pig was also demonstrated. 10 Tissue accommodation develops within chimeric pigs, before transplantation. 11, 12 In two recipients with preformed antibodies, pig heart xenografts developed neither hyperacute rejection nor AVR. Heart explants from chimeric pigs functioned for a prolonged period when perfused with plasma from sensitized sheep.
The feasibility of clinical xenotransplantation will depend on the prevention of rejection with acceptable levels of immune suppression. For the pig heart xenotransplants described here, immune suppression was limited to levels administered to allograft recipients. In this large animal study using chimeric donor pigs, AVR of pig xenografts was prevented without severe immune deficiency or toxicity.
METHODS

Animals and Care
The animals were housed at the University of Nebraska Medical Center and satellite facilities, which are AAALAC accredited. The Institutional Animal Care and Use Committee reviewed and approved all procedures used in this study. Veterinarians on the Committee monitored the study for full compliance.
The swine consisted of Yorkshire and Landrace crossbred gilts or sows. At the time of estrus, they were hand-bred. Pregnancy was confirmed by ultrasound examination at 35 days.
The sheep consisted of crossbreeds of Hereford, Dorset, and Rambouillet strains as well as Suffolk and Cheviot strains. The sheep were 6 to 12 months old and weighed 80 to 130 pounds. The sheep were not sensitized and did not have preformed cytotoxic antibodies to pig cells.
Intrauterine Injection of Pigs
The fetal pigs were injected at 43 to 46 days' gestation. On the day before injection, 35 to 45 mL marrow was aspirated from each recipient using sterile techniques. The mononuclear cells were partially depleted of CD4ϩ and CD8ϩ lymphocytes. Each fetal pig received 10 7 sheep mononuclear cells.
The gilts or sows were anesthetized and maintained on isoflurane. The abdomens were thoroughly prepared. The gilts and sows received intravenous vancomycin. Using ultrasound guidance, the marrow cells were infused into the piglet abdomens by percutaneous injection, injecting three to six pigs per litter.
If the sows and gilts did not farrow spontaneously by 2 days postterm, they either underwent induction of labor with prostaglandin-2-alpha or the pigs were delivered by cesarean section. At 2 to 4 days, a blood sample was drawn and analyzed for chimerism using flow cytometry and polymerase chain reaction (PCR).
The mononuclear cells were analyzed by flow cytometry using a monoclonal antibody specific for sheep class 1 major histocompatibility complex (MHC, 41-19, University of Melbourne, Australia) and fluorescein isothiocyanatelabeled secondary antibody. Chimerism was confirmed using PCR using primers for class I MHC antigen. Sheep and swine DNA have different mobilities on electrophoresis.
Heterotopic Heart Xenotransplants
When the chimeric pigs were 6 to 14 days of age, heterotopic pig heart xenografts were transplanted into the necks of the recipient sheep. The recipient was either the same sheep that provided the marrow for infusion or of the same strain as the marrow donor for five of the transplants. Seven days before surgery, the sheep received a single dose of cyclophosphamide (35 mg/kg, intravenous) to facilitate adoptive transfer of lymphocytes. A complete blood count was performed on the day of surgery and weekly thereafter.
The donor pig was anesthetized, intubated, and maintained on isoflurane. After preparation, the chest was opened, the pig was heparinized, and a sample of blood was drawn. Cold cardioplegia (Stanford) solution was infused and the heart was packed in iced saline slush. The heart was removed and prepared for transplant, ligating the superior and inferior vena cava and pulmonary veins. An atrial or ventricular septal defect was made. The spleen was removed and a cell suspension made.
The recipient sheep was intubated and maintained on isoflurane. The neck was sheared, prepared with Betadine, and opened. The left carotid artery and jugular vein were exposed. The sheep was heparinized. A sample of blood was taken. The aorta of the heart xenograft was anastomosed to the carotid artery (end-to-side) and the pulmonary artery was anastomosed to the jugular vein (end-to-side) using 7-0 proline sutures. The pig spleen cells (6 ϫ 10 8 to 4 ϫ 10 10 ) were infused. The clamps to the graft were then released and the graft was bathed in warm saline. If necessary, bretylium and defibrillation were used to restart the heart. The wound was closed in two layers.
Medication of Recipients and Monitoring of Grafts
Seven days before transplant, all recipient sheep received a single dose of cyclophosphamide (35 mg/kg) intravenously. Starting at 2 days pretransplant, oral cyclosporine (Neoral) was administered twice daily. Blood was analyzed for trough levels three times per week and the levels were maintained at 300 to 800 ng/mL. Solu-Medrol (1 g initial and tapered to 20 mg/d) was administered daily beginning 1 day before transplant.
Following the cyclophosphamide and biopsies, the sheep received a single injection of penicillin (900,000 units) intramuscularly. After the transplant, three daily injections of penicillin (900,000 units intramuscularly each) were given.
For the last nine transplants, the sheep received one low-dose aspirin (81 mg) per day by mouth to provide mild anticoagulation.
The grafts were monitored twice a day by palpation, assessing the rate and relative force, the diameter of the graft, and any evidence of local pathology such as hemorrhage, trauma, or infection.
On a weekly basis, the heart grafts were evaluated by ultrasound with a 7.5-MHz transducer. The thickness of the ventricular wall was measured for the left and right ventricles. Evidence of perfusion through the graft was assessed with Doppler. Percutaneous needle biopsies were performed using an 18-gauge needle. Two or three passes were performed for each biopsy. The biopsies were reviewed by a cardiovascular pathologist (SJR) without knowledge of the experimental group. Xenograft AVR was recognized according to histologic description. 13, 14 Acute cellular, resolving, and resolved rejection was graded according using the International Society of Heart and Lung Transplantation (ISHLT) grading system for acute heart graft rejection. 15 Blood was drawn at the time of transplant, just before infusion of the pig spleen cells, and weekly thereafter. A complete blood count was performed as well as basic metabolism profile. Serum was collected for antibodies and immunoglobulin analysis.
By design, the transplants were generally terminated and the sheep euthanized at 30 to 40 days posttransplant or on developing severe rejection. One recipient was followed for more than 70 days. A complete autopsy was performed, including gross and histologic evaluation of the graft and systemic tissues (tongue, skin, liver, intestine, native heart, lung, thymus, and spleen).
Experimental Design
The experimental group consisted of 13 sheep receiving splenocytes and a pig heart xenograft from a chimeric pig with sheep lymphocyte chimerism greater than 1% as measured by flow cytometry (chimerism 1-14%, median 4%). One control group ("noninjected") consisted of six sheep transplanted with splenocytes and a heart graft from an ageand strain-related donor pig. A second control group ("minimal chimerism") consisted of six sheep receiving splenocytes and a heart graft from injected pigs with minimal detectable chimerism. The blood or spleen cells showed chimerism by PCR (sensitivity to 1 in 10,000); however, the flow cytometry studies were negative (Ͻ1%). The number of splenocytes infused varied considerably, but there was no significant difference between the experimental group (median 4.0 ϫ 10 9 ) and either the noninjected control group (median 2.3 ϫ 10 9 ) or the minimal chimerism control group (median 6.5 ϫ 10 9 ). The sheep and grafts were monitored up to 70 days posttransplant. Sheep with severe rejection were euthanized in accordance with the IACUC-approved protocol. Four sheep with moderate diffuse cellular rejection (grade 3) and one with moderate focal cellular rejection (grade 2) were treated with pulse steroids consisting of 3 days of Solu-Medrol (1 g/d, intramuscular) and subsequently rebiopsied. The experimental sheep with AVR was treated with 3 days of pulse steroids. Three control sheep (one in the noninjected group, two in the minimal chimerism group) were treated with pulse steroids beginning with the first indication of rejection (at 4 or 5 days).
Five recipients were excluded from evaluation because local technical problems prevented adequate examination.
Laboratory Tests
Complete blood counts were performed using a Coulter counter. Differential analyses were performed manually. Blood urea nitrogen (BUN) and creatinine levels were determined as part of the basic metabolite panel. The values were compared with the normal levels for sheep. 16 Serum IgG and IgM levels were determined using radial immune diffusion assays.
Complement dependent lymphocytotoxic antibodies were assessed by incubating the test serum with normal pig lymphocytes and rabbit complement. The number of dead cells was determined with trypan blue. The test serum was serially diluted and the greatest dilution producing 20% or greater cytotoxicity determined.
The mononuclear cells were analyzed by flow cytometry using a monoclonal antibody specific for sheep class 1 MHC antigen (41-19, University of Melbourne, Australia) and FITC-labeled secondary antibody. Chimerism was confirmed using PCR on the blood or spleen cells. Primers for class 1 MHC antigen were used. Sheep and swine DNA demonstrated different mobilities for the corresponding product.
Vol
Statistical Analysis
Comparison of parametric values between groups used the nonpaired Student t test. Life-table analysis was performed using the Kaplan-Meier plot and log-rank (MantelCox) analysis. An observed difference between groups was considered significant at P Ͻ .05.
RESULTS
Clinical
The control groups consisted of sheep receiving splenocytes and heart xenografts from age-and strain-related pigs from either noninjected gilts (noninjected control group, n ϭ 6) or pigs delivered from injected gilts with minimally detectable chimerism (minimal chimerism control group, n ϭ 6). The sheep received posttransplant cyclosporine and tapered steroids. The grafts were monitored by clinical examination and ultrasound. The heterotopic xenografts in these groups beat for 3 to 8 days (mean 5.2 Ϯ 0.3 days). The grafts became enlarged and firm at 3 to 5 days. Ultrasound examination showed thickening of the ventricular wall.
The experimental group (n ϭ 13) received splenocytes and heart xenografts from pigs with chimerism detectable by flow cytometry. As with the controls, the sheep were treated posttransplant with cyclosporine and tapered steroids. The grafts were monitored by clinical examination, ultrasound, and weekly biopsies. The grafts did not show enlargement or thickening of the ventricular wall. They beat for 4 to 39 days (mean 18 Ϯ 3 days, P ϭ .01 vs. controls).
In the initial transplants, xenografts developed ischemic infarcts during the first week posttransplant, with thrombi in one or more coronary arteries. Subsequently recipients received mild anticoagulation, consisting of one low-dose aspirin (81 mg) per day. Among the experimental recipients, the grafts in the recipients receiving aspirin beat for 5 to 39 days (mean 22 Ϯ 4.7 days) compared with 4 to 14 days (mean 6.8 Ϯ 1.5 days) without aspirin (P ϭ .015). Aspirin did not improve the outcome with the control recipients (6 vs. 5 days). A Kaplan-Meier life-table analysis limited to the recipients receiving aspirin showed a significant prolongation of experimental xenografts based on graft contractions (median 24 days vs. 6 days, P ϭ .03). Because the ischemic infarcts were localized and prevented with mild anticoagulation, they were not considered to be a component of rejection in this study. Further analysis is therefore based on the development of AVR or cellular rejection in the perfused regions of the heart grafts.
All 12 grafts in the two control groups developed moderate or marked AVR (1 moderate, 11 marked) at 3 to 8 days. In contrast, only 1 of the 13 experimental xenografts developed AVR at 6 days. That recipient had low levels of chimerism in the donor pig (1%). The outcomes of the recipients are described in Table 1 . Figure 1 shows the Kaplan-Meier survival plot for heart xenografts until failure by either AVR or moderate diffuse (ISHLT grade 3) cellular rejection. In addition to the previously described recipient developing AVR, four experimental recipients developed diffuse moderate (grade 3B) acute cellular rejection (at 6, 6, 19, and 20 days). One recipient had an episode of focal moderate rejection (ISHLT grade 2) at 13 days.
Five of the experimental recipients with moderate cellular rejection (four with grade 3, one with grade 2) and one recipient with AVR were treated with pulse steroids, consisting of 1 g Solu-Medrol per day (intravenous) for 3 days. Follow-up histology showed significant improvement in those with cellular rejection. Four showed resolving rejection (ISHLT grade 1A). The graft with grade 2 cellular rejection improved to resolved rejection (ISHLT grade 0). The experimental recipient with AVR did not show improvement. Three minimal chimerism control recipients also received pulse steroids with the first evidence of rejection (graft enlargement). Those xenografts demonstrated marked AVR at necropsy. Figure 2 summarizes the hematologic values in the 13 experimental sheep. In general, the total white cell, lymphocyte, and platelet counts were within the normal limits of sheep throughout the course. One recipient was followed for over 70 days and had normal counts of white cells, lymphocytes, platelets, and levels of immunoglobulins.
Hematology and Immunology
Serum sheep immunoglobulins were measured. The IgG and IgM levels were in the normal range throughout the clinical course.
Lymphocytotoxic antibody titers were measured and compared with the control groups. Because of IACUC requirements, the sheep were killed after developing marked rejection. Thus, the noninjected and minimal chimerism control recipients could be assessed only at 1 week (5-7 days). Serum titers from experimental recipients at 1 week (5-7 days) were compared. The median titer of the experimental recipients was 5.5 (range 0 -32) compared with 160 (range 64 -256) for the control recipients (P Ͻ .001). The maximum titer in the experimental recipients was attained at 3 weeks, with three sheep having titers of 256 and two with titers of 1,024. None of the grafts had AVR.
The thymus tissue from the experimental sheep appeared histologically normal with cortex, medulla, Hassall's corpuscles, and a well-defined corticomedullary junction. The spleen tissue demonstrated normal-appearing white pulp with follicles containing germinal centers, mantle zone, and periarteriolar lymphocytes.
No special precautions were taken to prevent opportunistic infections in the recipients. Surgical procedures were performed in the usual sterile manner. Penicillin was the only antibiotic administered following the transplants or biopsies. One recipient with sinusitis (endemic in sheep) developed apparent septic shock.
Sections of skin, tongue, liver, and small intestine were examined for histologic evidence of graft-versus-host disease. Liver and intestinal sections from one recipient showed mild graft-versus-host disease. Intraductal lymphocytes were present in the liver, and increased intraepithelial lymphocytes and rare apoptotic lesions were evident in the intestine. This sheep had a disparity in strains between the marrow donor and the recipient and also developed AVR. The other tissue sections were normal. None of the other sheep showed evidence of graft-versus-host disease.
Heart Xenograft Pathology
The heart xenografts in the two control groups showed moderate to marked swelling starting at day 3 to 5 posttransplant. Ultrasound demonstrated marked thickening of the ventricular wall (2.8 Ϯ 0.23 times the initial thickness). At autopsy, the heart diameter averaged 1.65 Ϯ 0.09 times the diameter at transplant. The grafts had a shaggy hemorrhagic epicarditis. On cut section, the myocardium was deep red, consistent with interstitial hemorrhage.
The xenograft histology from the noninjected and minimal chimerism control groups showed moderate (n ϭ 1) or marked (n ϭ 11) AVR (Fig. 3A) . The myocardium was markedly congested with extensive and diffuse interstitial hemorrhage. The diffuse infiltrate consisted predominantly of large mononuclear cells including macrophages. The capillary and arterial endothelial cells were swollen. Numerous microscopic thrombi were evident. The lymphocytes and lymphoblasts amounted to less than 10% of the infiltrate. In three of the grafts, there were focal areas with infiltrates of lymphocytes and lymphoblasts consistent with additional acute cellular rejection, but the predominant process was vascular rejection.
The experimental group using chimeric donors (n ϭ 13) did not show significant swelling of the grafts or ventricular thickening at 5 to 7 days posttransplant. The ventricle was 1.29 Ϯ 0.12 times the initial thickness, significantly less than the control groups (P Ͻ .0002). The grafts at autopsy were only slightly larger than at transplant (ratio 1.23 Ϯ 0.09). For 12 of the 13 experimental grafts, the epicardial surface was smooth, glistening, and free of apparent pathology. One xenograft developed epicardial fibrosis secondary to a friction rub. On cut section, the viable myocardium of the xenografts had a normal brown coloration. Representative myocardial histology is shown in Figure 3B ).
Complications and Toxicity
In addition to the subjects listed in Table 1 , five experimental recipients were excluded from the study due to technical failure. Four had localized bleeding secondary to trauma, which necessitated euthanasia. The fifth developed a thrombus at the anastomosis of the carotid artery and aorta, making the graft totally avascular. These grafts were considered too early to evaluate. The graft of one experimental sheep euthanized at day 5 (hematoma) had mild cellular rejection (ISHLT grade 1A). The graft of a second experimental recipient euthanized at 6 days because of a hematoma was free of rejection (ISHLT grade 0). The other grafts were lost at 3 days or less and showed no evidence of rejection (ISHLT grade 0).
There was minimal evidence of toxicity related to the posttransplant suppression. Weekly serum samples were analyzed for creatinine and BUN. None of the specimens showed an elevated creatinine (Ͼ2.0 mg/dL for sheep). The weekly average ranged from 1.00 to 1.35. Three individual specimens had mildly elevated BUN levels (Ͼ26 mg/dL for sheep). One had a level of 31 on day 0, with normal levels on day 7 and thereafter. Two sheep had levels of 28 and 36 on day 35. One recipient experienced a loss of appetite at 20 days, leading to a 10% weight loss.
DISCUSSION
Using chimeric pig donors and modest immune suppression, AVR of the xenografts was prevented for the duration of this study, up to 70 days posttransplant. Significant acute cellular rejection was prevented in the majority of recipients. The early humoral response to pig cells was considerably reduced. The episodes of moderate cellular rejection that occurred were sensitive to pulse steroids, in a manner resembling allograft rejection. The recipients experienced few complications or toxicity related to immune suppression. The white cells and serum immunoglobulins were within normal limits throughout their clinical course.
Due to severe acute rejection of xenografts, the potential value of xenotransplantation has not yet been realized. In particular, AVR of xenografts has proved to be a major barrier. At 2 to 5 days, antibodies reacting with xenograft endothelial cells activate the endothelial cells and initiate coagulation, causing extensive interstitial hemorrhage. AVR is irreversible.
Efforts to prevent AVR have not been successful. Transgenic pigs with human complement inhibitors have been effective in preventing hyperacute rejection caused by preformed antibodies but have not been effective by themselves in preventing AVR. Agents that have been effective with cellular rejection of allografts have not been effective in preventing xenograft AVR.
Prevention of AVR has been accomplished in experiments. The conditions, however, may not be clinically acceptable. With complete depletion of baboon immunoglobulins, pig heart xenografts did not develop AVR. 17 Combining transgenic pigs expressing hDAF with marked immune suppression prevented AVR for up to 3 months. 18, 19 The white cell counts with this regimen, however, typically fell to 10% of normal values. 20 The immune suppression required for prolonged xenograft survival greatly exceeds the suppression generally effective for allografts. Yet the risk of infectious diseases for the xenograft recipient is greater, including both opportunistic and zoonotic infections. 21 The challenge for xenotransplantation, therefore, is to prevent pig xenograft rejection without subjecting the recipient to severe immune deficiency.
Two processes have been widely promoted to accomplish this goal. Specific immune tolerance for pig xenografts would reprogram the immune system to selectively ignore the pig xenograft, but react with other antigens. 22, 23 Accommodation would adapt or condition the xenograft to resist injury by preformed or induced antibodies. 1, 24, 25 The changes in the graft would not, in theory, inhibit the ability of the immune system to react with infectious agents.
The value of immune tolerance and accommodation has been demonstrated in pig-to-primate transplants, providing that these goals can be achieved. Immune tolerance to pig hematopoietic cells has been accomplished with mixed chimerism. After ablation of the recipient's immune system, it is reconstituted with a mixture of recipient and pig hematopoietic cells. Mixed chimerism has led to microchimerism of pig cells in baboons, persisting for many months. 4 Kidney xenografts, however, generally survived for only a few weeks. The transplantation of fetal pig thymus tissue to the recipient after immune ablation could further enhance tolerance. As the immune system rebuilds, T cells mature within the pig thymus and become tolerant to the major histocompatibility antigens expressed in the thymus. Thymus transplants have led to markedly prolonged survival of pig skin grafts 26 on mice and moderate but significant prolongation of pig skin grafts on a baboon. 27 These procedures expose the recipient to a period of severe immune deficiency until the immune system is reconstituted. In addition, tolerance may not be induced to tissue-associated antigens, such as endothelium. Chimerism alone has not proved to be effective in preventing AVR.
On an anecdotal basis, several investigators have observed continued survival of pig xenografts in primates, even with high titers of cytotoxic antipig antibodies. 6, 28 This has been attributed to accommodation. Most of the pig xenografts, however, are lost to AVR before accommodation is achieved. 29, 30 The induction of immune tolerance and tissue accommodation within the donor pig before transplantation provides advantages to the xenograft recipient. The recipient can be spared the period of immune ablation needed for tolerance. Tolerance can be induced to tissue-associated antigens. The risk of rejection while inducing tissue accommodation is greatly reduced. Antibodies do not need to be depleted. Multiple chimeric pigs can be produced. The success of immune tolerance and tissue accommodation can be determined and compared before transplantation.
This initial study of chimeric pig donors suggests that both immune tolerance and accommodation contributed to xenograft survival without severe immune deficiency. The Xenotransplants With Chimeric Pig Donors humoral response in the recipients was very low during the initial week, compared with the control sheep, suggesting tolerance. Five of the recipients later developed antipig antibody titers equal to or greater than 256 at 3 weeks posttransplant. Yet none of the grafts developed AVR, suggesting tissue accommodation.
The pig-to-sheep xenotransplant model was valuable in illustrating the potential clinical importance of using chimeric pig donors. Sheep approximate humans in size, mount a vigorous antipig antibody response, have a therapeutic index for cyclosporine comparable with humans, and routinely reject xenografts by AVR with standard immune suppression. 31, 32 There is little literature regarding pig-tosheep xenotransplants. However, even in newborn goats, pig heart transplants are consistently rejected by AVR at 6 to 8 days, with histopathology consistent with that observed in primate recipients. 33 The described observations also suggest studies for the further development of technology employing chimeric donors. Sheep cells constitutively express Gal(alpha)1-3Gal (alphaGal) and therefore do not make antibodies to alphaGal. The transplants should therefore be studied with primate recipients that have preformed and induced antibodies to alphaGal. Transplant studies should also be performed to separate tolerance from accommodation and determine the relative contribution of each process.
